Skip to main content

BioCommunique Article

Hibbs brings more than 25 years of legal and management expertise in clinical diagnostic market segment to Cadex Genomics

Cadex Genomics Builds Out Leadership Team with Election of Kathy Hibbs to Board as an Independent Director

  • 2019-10-22T19:14:00.000+0000
  • Bay Area
  • Author: Cadex Genomics

Cadex Genomics, developers of a real-time cancer therapy monitoring diagnostic, Alibrex, today announced the election of Kathy Hibbs, Esq. as an independent director.

Hibbs is the chief legal and regulatory officer at 23andMe. Prior to joining 23andMe, Hibbs served as senior vice president and general counsel, responsible for the legal, regulatory and business development functions at Genomic Health, Inc. Hibbs has also held related posts at Monogram Biosciences Inc., and Varian Medical Systems, Inc.

Hibbs is active in several industry groups, including AdvaMed and the Personalized Medicine Coalition (PMC). Hibbs holds a Juris Doctorate from the University of California, Hastings School of Law and a Bachelor of Arts in political science from the University of California, Riverside.

We are extremely pleased to have Kathy join our board,” said Bill Haack, president and CEO of Cadex Genomics. “Kathy brings a depth of leadership, knowledge and experience that will be invaluable to us as we approach the commercialization phase of the company.” “Cadex Genomics is taking a novel and compelling approach to cancer therapy monitoring,” said Kathy Hibbs, chief legal and regulatory officer for 23andMe. “I am excited to join such a dynamic team at this pivotal point in the company’s growth.”